-

Ology Bioservices Enters Phase 1 Clinical Trial for Anti-COVID-19 Monoclonal Antibodies

ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc. (Ology Bio), a biologics contract development and manufacturing organization (CDMO), announced today that it has begun dosing volunteers in a Phase 1 clinical trial with ADM03820, a cocktail of anti-SARS-CoV-2 monoclonal antibodies. This trial is part of a Department of Defense (DOD) award to manufacture and test anti-COVID-19 monoclonal antibodies. The study will randomize a total of 40 healthy subjects between the ages of 18-55 to receive either an intramuscular injection or intravenous infusion of either ADM03820 or placebo at two clinical sites.

“As both vaccines and monoclonal antibodies are important in the strategy for reducing the continued spread and related morbidity and mortality of COVID-19, Ology Bio is excited for this product to be entering the clinical trial phase,” said Peter H. Khoury, Ph.D., President and Chief Executive Officer of Ology Bio.

About Ology Bioservices Inc.

Ology Bio is a privately held, full-service Contract Development Manufacturing Organization (CDMO) serving both government and commercial clients, specializing in biologic drug substance manufacturing from early stage through commercial product. The company has 183,000 square feet of manufacturing, process development and QA/QC space in its state-of-the-art Advanced Development and Manufacturing Facility in Florida. The company’s infrastructure provides unique services to its clients, including full regulatory support from preclinical through licensure, clinical trial operational support and bioanalytical testing, as well as CGMP manufacturing up to Biosafety Level 3 (BSL3). Ology Bio has more than 20 years’ experience developing and manufacturing drugs and biologics for the U.S. government, with more than $1.8 billion in government contracts awarded. The team at Ology Bio has decades of experience manufacturing, developing and licensing vaccines and protein/antibody therapeutics. For more information, visit the company’s website at www.ologybio.com.

[The information contained in this press release does not necessarily reflect the position or the policy of the U.S. government and no official endorsement should be inferred.]

Contacts

Ology Bioservices Inc.
Robert V. House, Ph.D.
Senior VP, Government Contracts
301-276-7851
robert.house@ologybio.com

Surgence Communications Strategies
Wendy Crites Wacker, APR, CPRC
352-494-2129
wendy@surgencecs.com

Ology Bioservices Inc.


Release Summary
Ology Bioservices has begun dosing volunteers in a Phase 1 clinical trial with ADM03820, a cocktail of anti-SARS-CoV-2 monoclonal antibodies.
Release Versions

Contacts

Ology Bioservices Inc.
Robert V. House, Ph.D.
Senior VP, Government Contracts
301-276-7851
robert.house@ologybio.com

Surgence Communications Strategies
Wendy Crites Wacker, APR, CPRC
352-494-2129
wendy@surgencecs.com

Social Media Profiles
More News From Ology Bioservices Inc.

Ology Bioservices Awarded $37 Million by Department of Defense for Advanced Development of Anti-COVID-19 Monoclonal Antibody Cocktail

ALACHUA, Fla.--(BUSINESS WIRE)--The DOD has awarded Ology Bioservices with a $37 million agreement for the advanced development of an anti-COVID-19 monoclonal antibody cocktail....

Ology Bioservices Named 2020 Company Of The Year By BioFlorida

ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices Inc. was named the 2020 David J. Gury Company of the Year by BioFlorida....

Department of Defense Awards Ology Bioservices Contract to Manufacture and Test Novel Live Attenuated Tularemia Vaccine Candidate

ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices announced that the DOD has awarded the company with a contract to manufacture a novel live attenuated tularemia vaccine....
Back to Newsroom